On Wednesday, Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), lost -2.50% to $3.51.
On June 8, Idera Pharmaceuticals, declared that the company has reached a planned clinical research alliance with The University of Texas MD Anderson Cancer Center to advance clinical development of intratumoral TLR9 agonist in combination with checkpoint inhibitors. IMO-2125 is a TLR9 agonist which has been evaluated subcutaneously in over 80 human subjects, was well tolerated, and was shown to induce immune responses.
The company intends to initiate the first trial of the research alliance, a Phase 1/2 study to assess the safety and efficacy of Intratumoral IMO-2125 in combination with ipilimumab (a CTLA4 antibody) in patients with metastatic melanoma. In this trial, escalating doses of IMO-2125 will be administered intratumorally into a lesion, with a standard dosing regimen of ipilimumab. The primary objectives of the trial will be to determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLTs) of IMO-2125 when administered intratumorally in combination with ipilimumab, in addition to to determine the efficacy of the combination utilizing the immune-related response criteria (irRC). The company has already filed and received FDA feedback to a Pre-Investigational New Drug Application (PIND) for IMO-2125 and intends to submit an Investigational New Drug application (IND) and initiate the clinical study in the second half of this year. The trial will enroll about 45 patients. The company anticipates data to be accessible in 2016. The study will be led by Adi Diab, MD, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson. Additional trials as part of the broader, clinical research alliance are presently in the planning stages.
Idera Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, counting toll-like receptor targeting technology and gene silencing oligonucleotide technology.
Shares of Yelp Inc. (NYSE:YELP), declined -1.67% to $45.25, during its last trading session.
Yelp Inc., declared the launch of Yelp Philippines.
Starting, people across the Philippines are able to read reviews about great local businesses and create accounts on Yelp.com.ph to share their opinions. Yelp’s free iPhone and Android apps will be accessible in addition to its free suite of business owner tools: Yelp for Business Owners.
Yelp Inc. operates a platform that connects people with local businesses in the United States. Its platform covers various local business categories, counting restaurants, shopping, beauty and fitness, arts, entertainment and events, home and local services, health, nightlife, travel and hotel, auto, and others categories.
At the end of Wednesday’s trade, Shares of PAREXEL International Corporation (NASDAQ:PRXL), lost -7.73% to $66.96.
In conjunction with its Investor Day held on June 24, PAREXEL International Corporation (PRXL) has updated its forward-looking guidance for the fourth quarter of Fiscal Year 2015 (ending June 30, 2015) and for the full Fiscal Year 2015. It has also offered guidance for Fiscal Year 2016 for the first time. In addition, the Company declared the initiation of a Margin Acceleration Program.
Mr. Josef H. von Rickenbach, PAREXEL’s Chairman and Chief Executive Officer, stated, “As we finish Fiscal Year 2015 and look ahead to Fiscal Year 2016, we believe that we have good momentum, a strong and diversified backlog, and a healthy business development pipeline. Our priorities for the new year comprise solid revenue growth, in addition to improved operating profitability and double-digit growth in earnings per share. In conjunction with our new guidance we are also raising our long-term adjusted operating margin target from 12%-14% of service revenue to 13%-15% of service revenue. We are accelerating a number of our ongoing improvement plans, and as a result of these efforts, plan to restructure certain activities. We believe that this will strengthen the Company by increasing our competitiveness in the marketplace, and will assist us to deliver long-term sustainable growth in revenue and margins.”
PAREXEL International Corporation, a biopharmaceutical outsourcing services company, provides clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide.
Finally, Foot Locker, Inc. (NYSE:FL), ended its last trade with -0.46% loss, and close at $65.55.
On June 17, Foot Locker declared its partnership with ASICS America Corporation to launch its “Real Lives. Real Runners.” campaign, ahead of the 2015 TCS New York City Marathon. Whether it’s a mile or a marathon, all runners have a story, and this campaign will provide a platform to capture and share their stories.
Building on the successful 2014 “All Runners Welcome” campaign from Foot Locker and ASICS, “Real Lives. Real Runners.” invites filmmakers to identify authentic runners and document in a short film why they run and how running impacts their lives. The winning film will air nationally during the television broadcast of the 2015 TCS New York City Marathon, and the winning filmmaker will receive a cash prize from MOFILM, plus an all-expenses paid trip to Los Angeles for the annual MOFILM Awards.
Filmmakers can submit up to a three-minute piece, celebrating runners from all walks of life, with shortened versions of 30 and 60 seconds. Deadline for submissions is Sept. 7, 2015.
Foot Locker, Inc. operates as an athletic shoes and apparel retailer. The company operates in two segments, Athletic Stores and Direct-to-Customers. The Athletic Stores segment retails athletic footwear, apparel, accessories, and equipment under various formats, counting Foot Locker, Lady Foot Locker, Kids Foot Locker, Champs Sports, Footaction, and SIX:02, in addition to Runners Point, and Sidestep.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
